neoplasms

2 March, 2026

A breakthrough from Aragon opens new avenues of immunotherapy for rare blood diseases

A preclinical study by the IIS Aragón demonstrates, for the first time, the viability of a CAR-T therapy aimed at myeloproliferative neoplasms (rare blood diseases with limited therapeutic options).